Cases of syphilis and gonorrhoea have tripled and quadrupled, respectively, since 2015, highlighting the need for effective treatments.

The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the takeover was first disclosed.

Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.

As regulatory expectations rise and advanced therapies push cold-chain complexity, 3PLs are investing in validated infrastructure, network-wide quality systems, and data-driven visibility.